Vanda Pharmaceuticals
VNDA
NZ$7.85
Share price
-0.43%
Change (1 day)
-22.76%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : NZ$0.20 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are NZ$0.20 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | NZ$0.20 B | 27.44% |
| 2023-12-31 | NZ$0.16 B | -2.9% |
| 2022-12-31 | NZ$0.16 B | 29.6% |
| 2021-12-31 | NZ$0.13 B | 17.06% |
| 2020-12-31 | NZ$0.11 B | 2.81% |
| 2019-12-31 | NZ$0.10 B | 27.87% |
| 2018-12-31 | NZ$84.54 M | -18.9% |
| 2017-12-31 | NZ$0.10 B | -8.64% |
| 2016-12-31 | NZ$0.11 B | -2.4% |
| 2015-12-31 | NZ$0.11 B | 741.46% |
| 2014-12-31 | NZ$13.89 M | -88.49% |
| 2013-12-31 | NZ$0.12 B | -20.88% |
| 2012-12-31 | NZ$0.15 B | -20.14% |
| 2011-12-31 | NZ$0.19 B | -15.93% |
| 2010-12-31 | NZ$0.22 B | -18.54% |
| 2009-12-31 | NZ$0.27 B | 4037.9% |
| 2008-12-31 | NZ$6.74 M | -60.66% |
| 2007-12-31 | NZ$17.14 M | 27.09% |
| 2006-12-31 | NZ$13.48 M | 81.21% |
| 2005-12-31 | NZ$7.44 M | 193.68% |
| 2004-12-31 | NZ$2.53 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | NZ$103.17 B | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | NZ$123.39 B | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$193.90 B | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$125.80 B | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | NZ$196.97 B | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | NZ$0.46 M | -99.77% | 🇺🇸 USA |
 Merck MRK | NZ$111.95 B | 55,262.23% | 🇺🇸 USA |